Ocular Therapeutix, Inc.
OCUL · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $14,544 | $13,459 | $10,698 | $17,082 |
| % Growth | 8.1% | 25.8% | -37.4% | – |
| Cost of Goods Sold | $1,774 | $1,944 | $1,262 | $1,230 |
| Gross Profit | $12,770 | $11,515 | $9,436 | $15,852 |
| % Margin | 87.8% | 85.6% | 88.2% | 92.8% |
| R&D Expenses | $52,358 | $51,081 | $42,857 | $40,989 |
| G&A Expenses | $0 | $26,556 | $28,934 | $24,120 |
| SG&A Expenses | $29,110 | $28,075 | $30,496 | $25,439 |
| Sales & Mktg Exp. | $0 | $1,519 | $1,562 | $1,319 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $81,468 | $79,156 | $73,353 | $66,428 |
| Operating Income | -$68,698 | -$67,641 | -$63,917 | -$50,576 |
| % Margin | -472.3% | -502.6% | -597.5% | -296.1% |
| Other Income/Exp. Net | -$720 | -$173 | -$136 | $2,188 |
| Pre-Tax Income | -$69,418 | -$67,814 | -$64,053 | -$48,388 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$69,418 | -$67,814 | -$64,053 | -$48,388 |
| % Margin | -477.3% | -503.9% | -598.7% | -283.3% |
| EPS | -0.38 | -0.39 | -0.38 | -0.29 |
| % Growth | 2.6% | -2.6% | -31% | – |
| EPS Diluted | -0.38 | -0.39 | -0.38 | -0.29 |
| Weighted Avg Shares Out | 183,920 | 172,595 | 169,397 | 168,019 |
| Weighted Avg Shares Out Dil | 183,920 | 172,595 | 169,397 | 168,019 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3,729 | $3,455 | $3,826 | $4,671 |
| Interest Expense | $3,002 | $3,016 | $2,984 | $3,106 |
| Depreciation & Amortization | $1,072 | $1,026 | $981 | $951 |
| EBITDA | -$65,344 | -$63,772 | -$60,088 | -$44,331 |
| % Margin | -449.3% | -473.8% | -561.7% | -259.5% |